---
title: "Varegacestat (AL102) in Desmoid tumors: Pathophysiology"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Pathophysiology. Topics: Constitutive activation of the Wnt/β-catenin pathway, Nuclear β-catenin accumulation, Mutual exclusivity of CTNNB1 and APC mutations, Notch pathway cross-talk and overexpression, and 2 further topics. 6 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/pathophysiology"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Constitutive activation of the Wnt/β-catenin pathway

> “Approximately 85–90% of sporadic cases of DT show activating mutations in the N-terminal region of CTNNB1 (all of them in exon 3)”
> “making β-catenin more resistant to proteolytic degradation, leading to cytoplasmic accumulation of the protein and its subsequent translocation to the nucleus.”
> “In ~5–10% of patients, DT results from germline (i.e., in FAP) or sporadic loss-of-function mutations in the APC tumor suppressor gene.”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

> “Although the molecular pathogenesis of desmoid tumors is not fully understood, dysregulation of the Wnt/β-catenin pathway and consequent transcription of prosurvival and proliferative genes likely play a critical role.”

Source: [Kummar et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5455706/)

<a id="topic-2.2.1.4-2"></a>

### Nuclear β-catenin accumulation

> “Nuclear β-catenin expression was observed in 98% of specimens and intensity was inversely correlated with incidence of desmoid recurrence (P < 0.01).”

Source: [Lazar et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2570141/)

<a id="topic-2.2.1.4-3"></a>

### Mutual exclusivity of CTNNB1 and APC mutations

> “CTNNB1 mutations and APC mutations are mutually exclusive in DT, thus, detection of a somatic CTNNB1 mutation can help to exclude a syndromic condition.”
> “Either APC loss or CTNNB1 mutation can lead to DT development.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.1.4-4"></a>

### Notch pathway cross-talk and overexpression

> “Cross-talk between the Notch and Wnt pathways, as well as activation of the Notch pathway resulting from dysregulation of the Wnt pathway, suggest a possible therapeutic target for DT.”
> “Subsequent studies analyzed the expression of Notch pathway components in DT tissues and cell strains, and confirmed increased expression of HES1 in DT versus dermal scar tissue”
> “Dysregulation of the Wnt signaling pathway plays a key role in DT pathogenesis, however, as the result of crosstalk, Wnt dysregulation may lead to activation of the Notch pathway.”
> “The overexpression of Notch pathway components in DT provides a rationale for development of pharmacologic agents targeting Notch.”
> “Due to the role γ-secretase plays in Notch signaling through cleavage of the Notch intracellular domain (with subsequent translocation to the nucleus to activate gene transcription), γ-secretase inhibitors (GSIs) have emerged as a potential treatment for DT.”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

> “Activation of Notch pathway components in tumor samples from patients with aggressive fibromatosis has been demonstrated previously”

Source: [Kummar et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5455706/)

> “Desmoid tumors are driven by nuclear accumulation of β-CATENIN resulting from cross-talk between WNT and NOTCH pathways”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.2.1.4-5"></a>

### Hormonal influence on tumor biology

> “It also recognised that desmoid tumour biology is influenced by oestrogen exposure, which may be relevant to people with current or prior oestrogen exposure, regardless of gender identity.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.1.4-6"></a>

### CTNNB1 genotype and tumor behavior

> “Five-year recurrence-free survival was significantly poorer in 45F-mutated desmoids (23%, P < 0.0001) versus either 41A (57%) or nonmutated tumors (65%).”

Source: [Lazar et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2570141/)

> “DF harboring p.S45F was significantly associated with male sex (P = 0.03), non-abdominal wall sites (P = 0.05), pain (P = 0.007), and large tumor size (P = 0.025). CTNNB1 p.S45F mutation was not significantly associated with EFS, either in univariate (HR, 1.06; 95% CI, 0.65-1.73; P = 0.81) or in multivariate analysis (HR, 0.91; 95% CI, 0.55-1.49; P = 0.71).”

Source: [Penel et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35294527/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
